-1753896377077.webp&w=3840&q=75)
2025 NOSCM | Waldenstrom’s Macroglobulinemia
Overview
Dr. Morie Gertz reviewed Waldenstrom's macroglobulinemia, noting M spike, hyperviscosity, and lymphoplasmacytic cells. Treatments include rituximab-bendamustine and BTK inhibitors, with Zanubrutinib favored for lower toxicity. Patient input and individual factors guide therapy choices.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Morie A. Gertz, MD, MACP
Date of Release
July 30th, 2025
-1755991489210.webp&w=3840&q=75)
-1755991393648.webp&w=3840&q=75)